Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.
Unlock the market timeline & signal feed
8 signals in the last 90 days.
The order this company entered each market — oldest to newest
Korean News Portal Content
Korean News Portal Content
Sign up to see the full signal feed
How Samsung Biologics's international expansion compares to its competitors
Samsung BiologicsYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Samsung BiologicsYou | 0 | 0 | -100% | 8 | 57 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
The delivery of safe, high-quality medicines demands a culture where precision and compliance are deeply ingrained at every level. Dr Diane Black, EVP and Chief Quality Officer at Samsung Biologics, shares how our quality approach is put into practice through continuous process improvement. Our quality teams maintain a consistent presence on the manufacturing floor, providing real-time oversight and hands-on support throughout production. This close alignment strengthens process control, keeps p ...
EndedKOSPI rose 2.25% to 8228.70 driven by semiconductor stocks, with SK Hynix surging 9.31% and Samsung Electronics up 2.68%, while KOSDAQ fell 3.36% amid polarized market conditions.
Samsung Biologics estimates 150 billion won loss from union strike starting May 1st. Union demands 14% wage increase and 30 million won per person. Production of cancer and HIV drugs disrupted.
Samsung Biologics faces third day of full-scale strike with 2,800 workers participating. Company estimates 640 billion won in damages, exceeding Q1 operating profit. Labor-management gap remains over wage increases and bonuses.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Samsung Biologics's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
